# German Hodgkin Study Group

Source: https://onco.cc/companies/ghsg/  
OnCo record `ghsg` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Cologne-based group whose HD trials, from BEACOPP to BrECADD in HD21, have set the standard for treating Hodgkin lymphoma for four decades.

## Summary

Founded in 1978 by Volker Diehl and based at the University Hospital of Cologne, the GHSG has enrolled tens of thousands of patients in sequential HD trials that defined stage-adapted therapy. Its work produced the escalated BEACOPP regimen, showed PET-guided de-escalation is safe (HD16, HD18), and in HD21 showed brentuximab-based BrECADD is less toxic and at least as effective as BEACOPP in advanced disease. The group runs a central review panel for pathology and imaging and long-term survivorship studies of second cancers and cardiac toxicity. It sits within the Department I of Internal Medicine at Cologne.

## Fields

- Kind: Company
- Last checked: 2026-09-09
- Also known as: GHSG; Deutsche Hodgkin Studiengruppe
- Tags: cooperative-group
- HQ: Cologne
- Type: cooperative-group
- Website: https://www.ghsg.org

## Notes

- HD trial series (HD1-HD21)
- PET-guided treatment adaptation
- HD21 (BrECADD)
- Survivorship and late-effects research

## Sources

- GHSG: https://www.ghsg.org

## Connected records

- drugs: [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [FDG PET](https://onco.cc/technologies/fdg-pet/)
- companies: [German Lymphoma Alliance](https://onco.cc/companies/german-lymphoma-alliance/)
- institutions: [Uniklinik Köln (CIO)](https://onco.cc/institutions/uniklinik-koeln/)
- trials: [GHSG HD10](https://onco.cc/trials/hd10/), [GHSG HD16](https://onco.cc/trials/hd16/), [GHSG HD18](https://onco.cc/trials/hd18/), [GHSG HD21](https://onco.cc/trials/hd21/)
- people: [Andreas Engert](https://onco.cc/people/andreas-engert/), [Michael Hallek](https://onco.cc/people/michael-hallek/), [Peter Borchmann](https://onco.cc/people/peter-borchmann/)
- key papers: [Long-term follow-up of nodular lymphocyte-predominant Hodgkin lymphoma treated in the GHSG HD7 to HD15 trials](https://onco.cc/key-papers/paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020/), [PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group](https://onco.cc/key-papers/paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017/), [Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group](https://onco.cc/key-papers/paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019/)

---
JSON: https://onco.cc/api/v1/entities/ghsg.json